INEOS Quattro: conference call comments|NIH: improvement in certain indicators in H2, but still little visibility on M&A|Ardagh Group surprises with strong increase in glass EBITDA in Q4|Clariane : Satisfactory 2025 results thanks to strong recovery in H2 25 and B2/B+ ratings assigned by Moody’s and S&P|
INEOS Quattro: conference call comments|NIH : amélioration de certains indicateurs au S2 mais toujours peu de visibilité sur le M&A|Ardagh Group surprend avec une forte hausse de l’EBITDA verre au T4|Clariane : Résultats 2025 satisfaisants grâce à un bon rattrapage au 2nd semestre et ratings B2/B+ attribués par Moody’s et S&P|
Full-year 2025 results Solid 2025 resultsDebt reduction trajectory confirmedGrowth objectives for 2025-2028 All tables are available in the PDF. Successful plan to strengthen the financial position and confirmed debt reduction trajectory: Finalised €1 billion disposal plan at an average multiple of c.14X EBITDANormalised access to financing, with a €500 million bond issueReduction in net financial debt (excluding IFRS 16 and IAS 17) of €390 million compared to 31 December 2024, resulting in a decrease in Wholeco leverage(1) to 5.1x Clariane receives inaugural corporate ratings from two...
Résultats annuels 2025 Résultats 2025 solidesTrajectoire de désendettement confirméeObjectifs de croissance à horizon 2028 L’ensemble des tableaux sont disponibles dans le PDF Succès du plan de renforcement de la structure financière et trajectoire de désendettement confirmée : Plan de cession de €1md finalisé à un multiple moyen de c.14X l’EBITDAAccès normalisé au financement, avec une émission obligataire de €500mRéduction de la dette financière nette (hors IFRS 16 et IAS 17) à hauteur de -€390m par rapport au 31 décembre 2024, se traduisant par une baisse du levier Wholeco(1) à 5,1x Ob...
A director at Tikehau Capital bought 15,745 shares at 17.261EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.